Advance notice of 1 February 2025 change in Authority level for saxagliptin with dapagliflozin (Qtern^® 5/10)

Page last updated: 1 August 2024

A change to the restriction type for saxagliptin with dapagliflozin (Qtern^® 5/10) from Authority Required (STREAMLINED) to Authority Required (telephone or electronic) is intended to take effect from 1 February 2025.

This is related to the November 2022 Pharmaceutical Benefits Advisory Committee consideration of the Drug Utilisation Sub-Committee analysis of medicines for the treatment of type 2 diabetes. Further information is available below:

• DUSC analysis of T2DM medicines – PBAC 11-2022 (Word 34KB)
• DUSC analysis of T2DM medicines – PBAC 11-2022 (PDF 213KB)

For any enquiries, please contact PBS@health.gov.au.